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Background: Oral cancer is a major global health problem. The complexity of histological prognosticators in oral
cancer makes it difficult to compare the benefits of different treatment regimens. The Taiwanese National Health
database provides an opportunity to assess correlations between outcome and treatment protocols and to compare
the effects of different treatment regimens. However, the absence of indices of disease severity is a critical problem.
The aim of this study was to ascertain how accurately we could assess the severity of oral cancer at the time of initial
diagnosis on the basis of variables in a national database.
Methods: In the cancer registry database of a medical center in Taiwan, we identified 1067 histologically confirmed
cases of oral cancer (ICD9 codes 140, 141 and 143–145) that had been first diagnosed and subjected to initial
treatment in this hospital. The clinical staging status was considered as the gold standard and we used concordance
(C)-statistics to assess the model’s predictive performance. We added the predictors of treatment modality, cancer
subsite, and age group to our models.
Results: Our final overall model included treatment regimen, site, age, and two interaction terms; namely, interactions
between treatment regimen and age and those between treatment regimen, site, and age. In this model, the
C-statistics were 0.82–0.84 in male subjects and 0.96–0.99 in female subjects. Of the models stratified by age, the
model that considered treatment regimen and site had the highest C-statistics for the interaction term, this value
being greater than 0.80 in male subjects and 0.9 in female subjects.
Conclusion: In this study, we found that adjusting for sex, age at first diagnosis, oral cancer subsite, and therapy
regimen provided the best indicator of severity of oral cancer. Our findings provide a method for assessing cancer
severity when information about staging is not available from a national health-related database.
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Oral cancer is a major health problem, the worldwide
annual incidence being 274,300 cases with 128,000 deaths;
two-thirds of this burden is in developing countries [1].
Despite considerable advances in diagnostic and thera-
peutic techniques, oral cancer continues to portend a poor
prognosis. We surveyed available published reports and
found that the effect of treatment regimen or other
prognosis-related factors is often uncertain and controver-
sial [2-5]. The complexity of histological prognosticators* Correspondence: psho@kmu.edu.tw
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reproduction in any medium, provided the orin oral cancer likely partly accounts for this because it
makes it difficult to compare the benefits of different
treatment regimens; small samples are another limitation
of previous studies [6-8].
The Taiwan National Health Insurance program, which
has operated since 1995, enrolls almost 99% of the inhabi-
tants of Taiwan and is contracted with 97% of hospitals
and clinics throughout the nation [9]. It therefore provides
an opportunity to assess correlations between outcome
and treatment protocol and thus compare the effective-
ness of different treatment regimens. However, the major
purpose of this program concerns costs of medical
services. In general, lack of information about disease
severity is a critical problem when analyzing a population
database. Anatomic site and disease stage are the mostLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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oral cancer after various treatment regimens [10-13]. The
aim of this study was to try to assess how accurately the
severity of oral cancer at the time of first diagnosis can be
assessed on the basis of variables commonly available in
national databases.Table 1 Relevant clinical characteristics of patients with
oral cancer
Male (n = 995) Female (n = 72)
N % N %
Age
20-44 265 26.63 11 15.28
45-65 610 61.31 32 44.44
≧65 120 12.06 29 40.28
Stage
I 199 20.00 24 33.33
II 137 13.77 4 5.56
III 284 28.54 11 15.28
IV 375 37.69 33 45.83
Site
Lip 48 4.82 4 5.56
Tongue 307 30.85 27 37.50
Gun 83 8.34 8 11.11
Floor of mouth 26 2.61 4 5.56
Palate 60 6.03 4 5.56
Buccal 302 30.35 16 22.22
Others and unspecified
parts of mouth
169 16.98 9 12.50
Treatment
S alone 350 35.18 28 38.89
RT alone 5 0.05 0 0.00
CT alone 302 30.35 19 26.39
S + RT 60 6.03 7 9.72
S + CT 139 13.97 11 15.28
RT + CT 69 6.93 4 5.56
S + RT + CT 70 7.04 3 4.17
S: surgery; R: radiation; C: chemotherapy.Methods
Database
We used data from a cancer registry database of a medical
center in Taiwan. In our study, we included all patients
with oral cancer (ICD9 codes 140, 141, 143–145) who had
been first diagnosed and undergone initial treatment in
this hospital from 1 January 2002 to 31 December 2007.
All 1067 of the oral cancer subjects included in the
database had been histologically confirmed and staged
according to the TNM staging system of the Union for
International Cancer Control [14]. Most study subjects had
squamous cell carcinoma (SCC; 971 cases, 91%); 577 of
these (54.08%) were well differentiated and 290 (27.18%)
moderately differentiated. The Institutional Review Board
of Kaohsiung Medical University Hospital reviewed and
approved our proposal for use of the database (KMUH-
IRB-980174).
Data concerning sex, age at first diagnosis, oral cancer
subsite (lip, tongue, gum, floor of the mouth, and other
sites), clinical stage, and therapy regimen were collected
from the database. We considered seven different treat-
ment regimens in this study; all were based on a combin-
ation of surgery, radiotherapy, and chemotherapy. The
gold standard for classifying oral cancer is considered clin-
ical stage, and we tried to classify it as accurately as pos-
sible by using available personal and medical intervention
variables. We performed the χ2 test to ascertain which
individual variables significantly contributed to the accur-
acy of staging. To assess the accuracy of our model’s pre-
dictive performance, we performed multivariate logistic
regression analyses and used concordance (C) statistics. In
the logistic regression analysis models, we included: (i)
treatment modality (the categories were surgery only; radi-
ation only; chemotherapy only; surgery and chemotherapy;
surgery and radiation; radiation and chemotherapy; sur-
gery, and radiation and chemotherapy; (ii) cancer subsite
(lip [140], tongue [141], gum [143], floor of mouth [144],
and other [145]); (iii) age group (20–44 years, 45–64 years
and ≥65 years); and (iv) interactions of these treatments
and sites.
A C-statistic of 1.0 represents perfect sensitivity and
specificity; whereas a C-statistic of 0.5 represents an essen-
tially worthless test. The C-statistic is an accuracy measure
that can be used for ordinal or nominal outcomes. In this
study, the C-statistic is a measure of the accuracy with
which the model discriminates between patients who werediagnosed as early stage and those who were diagnosed as
advanced stage.
Results
More than 90% of our cases were male (995/1067). The
mean first diagnosed age was 51.58 years (standard
deviation (SD) = 11.12); 51.08 years (SD = 10.67) in male
subjects and 58.64 years (SD = 14.44) in female subjects.
More than 50% of all cases were in the age group of 45–65
years at the time of diagnosis; 60% of male subjects were in
this age group. About 27% of male subjects were diagnosed
before the age of 45 years, but only 15% of women. Rele-
vant clinical variables at time of diagnosis are shown in
Table 1. More than 50% of cases were first diagnosed at an
advanced stage (III or IV), especially in men (>65%).
Tongue and buccal mucosa were the dominant subsites of
oral cancer in our study. About 30% of oral cancer in men
originated in the tongue and 30% in the buccal mucosa;
Table 2 Distribution of relevant factors in male patients according to clinical stage
Male
Stage I versus II-IV Stage I-II versus III-IV Stage I-III versus IV
Stage I Stage I-II Stage I-III
Total N % P-value N % P-value N % P-value
Age 0.0056 0.0423 0.9638
20-44 265 42 15.85 78 29.43 164 61.89
45-64 610 121 19.84 207 33.93 380 62.30
> = 65 120 36 30.00 51 42.50 76 63.33
Site <.0001 <.0001 <.0001
Lip 48 13 27.08 19 39.58 38 79.17
Tongue 307 84 27.36 133 43.32 233 75.90
Gingiva 83 5 6.02 13 15.66 25 30.12
Floor of mouth 26 11 42.31 15 57.69 19 73.08
Others 531 86 16.20 156 29.38 305 57.44
Treatment <.0001 <.0001 <.0001
S 346 142 40.57 215 61.43 305 87.14
RT 5 2 40.00 2 40.00 2 40.00
CT 302 18 5.96 38 12.58 109 36.09
S + RT 60 11 18.33 18 30.00 43 71.67
S + CT 139 18 12.95 43 30.94 92 66.19
RT + CT 69 0 0.00 4 5.80 23 33.33
S + RT + CT 70 8 11.43 16 22.86 46 65.71
S: surgery; R: radiation; C: chemotherapy.
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most common subsite. Surgery alone and chemotherapy
alone were the two most commonly administered treat-
ment regimens.
Tables 2 and 3 show the distribution of relevant factors
in each sex according to clinical stage. In male patients,
age, site, and treatment regimens were significantly associ-
ated with clinical stage (stage I vs II–IV and clinical stage
I–II vs III–IV). However, for clinical stages I–III versus IV,
age was not a significant factor, whereas site and treat-
ment were. In female patients, age was not a significant
factor for any of these comparisons. Site was the only fac-
tor that was statistically significantly associated with all
comparison situations. The factor of treatment regimen
showed different patterns of association for different
staging combinations; however, none of these were statis-
tically significant because there too few cases in any one
category of treatment regimen. Tables 4 and 5 show the
stepwise logistic regression models with which we exam-
ined the accuracy of the different predictors. In Model 1
of Table 4, only treatment regimens are considered; the C-
statistics are all 0.76 for the various combinations com-
pared in male subjects and 0.83–0.85 in female subjects.
Model 2 included only site; the C-statistics are 0.60–0.64
in male patients and 0.77–0.82 in female patients. Model
3 included treatment regimen and site; the C-statistics are0.78–0.79 in male subjects and 0.91–0.96 in female sub-
jects. Interactions between treatment regimens and sites
are considered in Model 4; the C-statistics are 0.79–0.81
in male patients and 0.94–0.97 in female patients. Follow-
ing Model 4, age was considered in Model 5; the C-
statistics are 0.80–0.82 in male subjects and 0.96-0.99 in
female subjects. The final model shown is Model 6, which
included treatment regimen, site, age and two interaction
terms; namely, the interaction effect of treatment regi-
men/age and of treatment regimen/site/age. The C-
statistics in Model 6 are 0.82–0.84 in male patients and
0.96–0.99 in female patients. In Table 5, the models are
stratified by age and the accuracy evaluated by the predic-
tors of treatment regimen and site. There are four models
in this table; these consider treatment regimen, site, treat-
ment regimen, and site, and adding the interaction terms
of the two factors in each of Models 1, 2, 3, and 4 separ-
ately. For each stratified group, Model 4 has the highest
C-statistics, the values being greater than 0.80 in male
patients and 0.9 in female patients. The accuracy tended
to be better in older age groups, but we found no signifi-
cant variations in the various age groups.
Discussion
Knowledge of the anatomy and disease staging is essen-
tial to optimal treatment planning [15]. Some anatomic
Table 3 Distribution of relevant factors in female patients according to clinical stage
Female
Stage I versus II-IV Stage I-II versus III-IV Stage I-III versus IV
Stage I Stage I-II Stage I-III
N % P-value N % P-value N % P-value
Age 0.2566 0.4916 0.4026
20-44 6 54.55 6 54.55 8 72.73
45-64 10 31.25 11 34.38 16 50.00
> = 65 8 27.59 11 37.93 15 51.72
Site 0.0015 <.0001 0.0005
Lip 2 50.00 3 75.00 3 75.00
Tongue 16 59.26 19 70.37 23 85.19
Gingiva 1 12.50 1 12.50 2 25.00
Floor of mouth 2 50.00 2 50.00 2 50.00
Others 3 10.34 3 10.34 9 31.03
Treatment
S 17 60.71 20 71.43 24 85.71
RT 0 0.00 0 0.00 0 0.00
CT 0 0.00 0 0.00 3 15.79
S + RT 4 57.14 4 57.14 6 85.71
S + CT 2 18.18 3 27.27 5 45.45
RT + CT 1 25.00 1 25.00 1 25.00
S + RT + CT 0 0.00 0 0.00 0 0.00
S: surgery; R: radiation; C: chemotherapy.
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with poor outcomes because of their rich lymphatic
drainage and difficulty in evaluating the extent of local
invasion, and therefore in selecting an appropriate man-
agement strategy [16]. Vascular and lymphatic networks,Table 4 Staging accuracy according to logistic regression mo





Stage I versus II-IV
Male 0.76 0.62 0.79
Female 0.83 0.77 0.91
Stage I-II versus III-IV
Male 0.76 0.60 0.78
Female 0.85 0.82 0.96
Stage I-III versus IV
Male 0.76 0.64 0.79
Female 0.85 0.78 0.93which vary between different anatomic sites, may influ-
ence tumor evolution and hence the outcome; thus,
SCCs at the base rather than the oral part of the tongue
have a higher rate of metastasis [17]. Cancer staging
reflects both homogeneous survival data and importantdels evaluating the variables of treatment, site, and age













Table 5 Accuracy of each model according to logistic
regression analysis of various combinations of predictors
Model 1 Model 2 Model 3 Model 4
Treatment ˇ ˇ ˇ




Stage I versus II-IV
20-44 0.76 0.60 0.78 0.83
45-64 0.78 0.62 0.80 0.82
> = 65 0.77 0.68 0.81 0.86
Stage I-II versus III-IV
20-44 0.75 0.63 0.78 0.83
45-64 0.77 0.58 0.78 0.79
> = 65 0.81 0.68 0.86 0.90
Stage I-III versus IV
20-44 0.75 0.61 0.79 0.81
45-64 0.77 0.64 0.79 0.81
> = 65 0.76 0.73 0.86 0.89
Female
Stage I versus II-IV
20-44 0.93 0.70 1.00 1.00
45-64 0.87 0.82 0.89 0.92
> = 65 0.88 0.92 0.98 0.98
Stage I-II versus III-IV
20-44 0.93 0.70 1.00 1.00
45-64 0.90 0.85 0.93 0.95
> = 65 0.87 0.97 1.00 1.00
Stage I-III versus IV
20-44 0.98 0.77 0.98 0.98
45-64 0.91 0.87 0.96 0.96
> = 65 0.84 0.86 0.92 0.94
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options. Differentiation between stages I or II and stages
III or IV of oral SCCs is most important for treatment
planning, because early-stage tumors (stages I and II)
typically require only single-modality therapy (mostly
surgical resection), whereas stage III and IV tumors may
require multimodality therapy with a combination of
chemotherapy, radiation, and surgical resection. The
appropriate therapeutic modalities depend on the site of
origin of the primary tumor [18]. Population-based
administrative data are an effective source of informa-
tion about chronic disease or for cancer surveillance.
However, the ways in which data can be extracted from
such databases differ; in practice certain categories of
clinical information may be unavailable.This study provides a method for adjusting for cancer
severity when staging information is not available. We
found that the severity of oral cancer can be assessed
based on sex, age at first diagnosis, oral cancer subsite,
and therapy regimen with an accuracy of 84% in male
subjects and more than 96% in female subjects. In
Taiwan, oral cancer is a male-dominant cancer, the male:
female ratio being 9:1 [19]. More than 70% of men with
oral cancer have the habits of both chewing and smok-
ing tobacco, whereas only approximately 10% of female
patients have these habits [20]. Although some studies
have failed to find an association between prognosis and
smoking tobacco or consuming alcohol [21], most
authors have reported higher mortality in smokers and
alcohol drinkers [22,23]. In a study from Taiwan [21], Lo
et al. reported that areca quid chewing is also correlated
with a poor prognosis. Smokers and alcohol drinkers
seem to be at higher risk of developing second primary
oral cancers than nonsmokers and nondrinkers; thus,
they face worse outcomes [24,25]. In our study, we
found that the sex of the patient seemed to affect the
choice of treatment plan: a higher proportion of male
than female patients had undergone combined multi-
modality therapy, especially those with early-stage dis-
ease. This finding may be related to the sexes having
different habits; it requires further study.
Previous studies have suggested that sex differences in
oral cancer prognosis are attributable to a delay in seeking
medical care and differences in rate of compliance with
recommended treatment. Some studies have reported
lower survival rates in female subjects [22,26], whereas
others have found no sex-based difference in prognosis
[21,27,28]. A correlation between prognosis and age is
controversial; some authors reporting they are unrelated
and others having found that older patients have worse
prognoses [22,23]. Most researchers accept that disease
staging has a crucial influence on outcome [21,28-30].
This study has some limitations. Patients were included
on the basis of a previous diagnosis of oral cancer. The
training and expertise of the personnel who performed
the pathological assessments is unknown; therefore, we
are unable to determine the reliability of their findings.
Measurement methods and diagnostic criteria were also
likely variable. However, because the database used was
from a medical center, its accuracy is reliable.Conclusion
The main conclusion of this study is that adjusting for
sex, first diagnosed age, oral cancer subsite, and therapy
regime facilitates accurate assessment of the severity of
oral cancer. Our findings provide a method for adjusting
for cancer severity when staging information is not avail-
able from national health-related databases.
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